Vericel Corporation $VCEL Stock Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC decreased its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 24.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,573,043 shares of the biotechnology company’s stock after selling 510,789 shares during the period. Vericel comprises approximately 1.9% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 19th biggest holding. Conestoga Capital Advisors LLC’s holdings in Vericel were worth $63,142,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. MCF Advisors LLC boosted its position in Vericel by 293.0% during the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 583 shares during the period. Ameritas Advisory Services LLC acquired a new stake in Vericel in the 2nd quarter worth approximately $36,000. Allworth Financial LP acquired a new position in Vericel in the 2nd quarter valued at $60,000. Integrated Wealth Concepts LLC acquired a new position in shares of Vericel during the 2nd quarter worth about $72,000. Finally, GAMMA Investing LLC increased its position in Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 283 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on VCEL shares. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research note on Thursday, July 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. TD Cowen upped their target price on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Truist Financial lowered their price objective on Vericel from $58.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Vericel in a research note on Tuesday, July 28th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.20.

Vericel Stock Up 10.7%

VCEL stock opened at $45.48 on Thursday. The company has a market cap of $2.33 billion, a price-to-earnings ratio of 87.43 and a beta of 1.08. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $49.32. The business has a 50 day moving average price of $40.56 and a two-hundred day moving average price of $38.73.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.